University of Oxford

Academic Institute

Daniel Prieto-Alhambra - Chief Investigator - University of OxfordEng Hooi Tan - Corresponding Applicant - University of OxfordAntonella Delmestri - Collaborator - University of OxfordKatia Verhamme - Collaborator - Erasmus University Medical Center ( EMC )

CPRD845

Asthma is a prevalent chronic condition affecting 5-10% of the general population. In patients with asthma, the airways – via inflammation – might narrow, swell, and produce extra mucus. Unfortunately, asthma cannot yet be cured but the symptoms can be controlled. Medical therapy in asthma consists of anti-inflammatory drugs (mainly inhaled corticosteroids (ICS)) and bronchodilators (drugs to open the airways e.g.B2 agonists or muscarinic antagonists). Asthma treatment is tailored via a step-up or step-down approach. In patients with uncontrolled asthma, despite treatment with medium dose ICS in combination with a long acting B2 agonist (LABA), guidelines suggest to either (1) increase to high dose ICS+LABA or (2) add a long acting muscarinic antagonist (LAMA) on top of medium dose ICS+LABA. Physicians might (3) not only increase the dose of ICS but also add a LAMA resulting in triple therapy of high dose ICS+LABA+LAMA. It is unknown which patients benefit most from the treatment options as described above.

Background:

24/02/2021

Release